In a report released on July 2, from UBS maintained a Buy rating on Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H, with a price target of H...
Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H has an analyst consensus of Strong Buy, with a price target consensus of HK$88.60.
Based on Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of HK$9.27 billion and a net profit of HK$2.6 billion. In comparison, last year the company earned a revenue of HK$7.69 billion and had a net profit of HK$2 billion
In a report released on May 28, from UBS maintained a Buy rating on Zhongsheng Group Holdings Ltd., with a price target of…
In a report released on July 23, from UBS maintained a Buy rating on Shanghai MicroPort MedBot (Group) Co., Ltd. Class H, with a…
UBS analyst maintained a Buy rating on China Hongqiao Group Ltd. on May 28 and set a price target of HK$46.10. The company’s…
In a report released on June 17, from UBS maintained a Buy rating on Shanghai MicroPort MedBot (Group) Co., Ltd. Class H, with a…
In a report released on June 25, from UBS maintained a Buy rating on CanSino Biologics, Inc. Class H, with a price target of…
In a report released on May 28, Jacqueline Du from Goldman Sachs maintained a Buy rating on Wuxi Lead Intelligent Equipment Co.,…
